Literature DB >> 1469295

Effective enrichment of murine epidermal Langerhans cells by a modified(mismatched) panning technique.

F Koch1, E Kämpgen, G Schuler, N Romani.   

Abstract

A method for the enrichment of murine epidermal Langerhans cells (LC) is described in detail. It is based on positive selection of LC from pre-enriched fresh or cultured epidermal cell suspensions derived from ear skin by a modified panning technique. The method uses the interspecies cross-reactivities of anti-immunoglobulin antibodies: when LC in an epidermal cell suspension are labeled with mouse anti-major histocompatibility complex (MHC) class II antibodies they bind to petri dishes coated with anti-rat immunoglobulin antibodies. We therefore call this method "mismatched panning." After rinsing off non-adherent cells, the adherent LC can easily be dislodged by adding excess amounts of rat immunoglobulins, which effectively compete with the LC-bound mouse anti-MHC class II antibodies for binding to the petri dish. Using this modified panning technique, both fresh and cultured LC could be enriched up to more than 90% purity. From one ear, 2.0-3.0 x 10(4) fresh LC and 3.0-4.5 x 10(4) cultured LC could be obtained. Of all LC present in a primary, unenriched epidermal cell suspension, 40-60% were recovered when panned immediately after isolation of the epidermal cells and 50-75% when panned after 3 d of epidermal cell culture. Viability of panned LC was consistently more than 90%. Antigen presenting and T-cell-stimulating capacity of LC and responses to the cytokines granulocyte/macrophage colony-stimulating factor and tumor necrosis factor-alpha were not impaired by this panning procedure. The major advantage of this method compared to pre-existing panning techniques is the ease with which adherent LC can be dislodged from the panning dishes. Because the elution procedure is very gentle, virtually all panned LC are viable. As a consequence, good yields of highly enriched LC can be obtained in a reasonable time.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469295     DOI: 10.1111/1523-1747.ep12614764

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Human decidua contains potent immunostimulatory CD83(+) dendritic cells.

Authors:  U Kämmerer; M Schoppet; A D McLellan; M Kapp; H I Huppertz; E Kämpgen; J Dietl
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

2.  Retrovirus-induced immunosuppression via blocking of dendritic cell migration and down-regulation of adhesion molecules.

Authors:  D I Gabrilovich; G M Woods; S Patterson; J J Harvey; S C Knight
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

3.  CD207+ Langerhans cells constitute a minor population of skin-derived antigen-presenting cells in the draining lymph node following exposure to Schistosoma mansoni.

Authors:  Supeecha Kumkate; Gavin R Jenkins; Ross A Paveley; Karen G Hogg; Adrian P Mountford
Journal:  Int J Parasitol       Date:  2006-11-27       Impact factor: 3.981

4.  CD34+ -derived Langerhans cell-like cells are different from epidermal Langerhans cells in their response to thymic stromal lymphopoietin.

Authors:  Van Anh Nguyen; Sandrine Dubrac; Markus Forstner; Otto Huter; Barbara Del Frari; Nikolaus Romani; Susanne Ebner
Journal:  J Cell Mol Med       Date:  2011-09       Impact factor: 5.310

5.  Understanding the dendritic cell lineage through a study of cytokine receptors.

Authors:  E Kämpgen; F Koch; C Heufler; A Eggert; L L Gill; S Gillis; S K Dower; N Romani; G Schuler
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

6.  Allergenic Can f 1 and its human homologue Lcn-1 direct dendritic cells to induce divergent immune responses.

Authors:  Beate Posch; Christian Irsara; Fabian S Gamper; Martin Herrmann; Daniel Bindreither; Dietmar Fuchs; Norbert Reider; Bernhard Redl; Christine Heufler
Journal:  J Cell Mol Med       Date:  2015-07-27       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.